Chronic Idiopathic Constipation (CIC) Drugs Market 2016 to 2022 - Size, Share, Analysis, Trends and Forecast By Credence Research

The latest market report published by Credence Research, Inc. “Global Chronic Idiopathic Constipation (CIC) Drugs Market  was valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4% from 2016 to 2022; where Europe has the largest market share.
The purpose of the report is to illustrate the state of the market of Chronic Idiopathic Constipation (CIC) Drugs, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2016, and also, to build a forecast for the growth of the industry in the medium term until 2022.
Market Insights:
Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder. The currently available treatment options, both prescription based and OTC have demonstrated limited efficacy in a considerable set of patients. Thus there is a major demand for more effective medications for the treatment of CIC. Linaclotide is a secretagogue and has novel action mechanism; it has low oral bioavailability and has demonstrated the least systemic side effects. Through several clinical trials, Linaclotide has demonstrated greater efficacy in treating both CIC and irritable bowel syndrome induced constipation.
Currently North America is the largest regional market for CIC drugs at a market share of approximately 50%. It is also expected that the region will progress at the fastest CAGR of above 8% during the forecast period. Higher awareness among physicians and patient population significantly contribute the market growth in the region. Earliest commercialization of the drug in the US also adds up to the high demand of the drug in North America market. On the other hand, gradual introduction of Linaclotide in other developing markets will facilitate market growth in Asia Pacific market. China, Japan, Australia and India are the major national markets that are expected to give highest revenue contributions to the Asia Pacific CIC drugs market. Also, supporting the established fact of correlation between age and risk of CIC, it is reported that China and Japan will be the largest national markets for CIC drugs in Asia Pacific.
 Download Free Request Checkout: https://www.credenceresearch.com/checkout/57738
Leading Players:

• Actavis
• Chugai Pharmaceutical
• Ferring International Center S.A.
• Synergy Pharmaceuticals
• Pfizer
• GlaxoSmithKline
• Roche Holding AG
• Sanofi
• Bayer AG
• Salix Pharmaceuticals Ltd
• Sucampo Pharmaceuticals Inc  

Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Chronic Idiopathic Constipation (CIC) Drugs buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
Browse here for full report with Toc: https://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Chronic Idiopathic Constipation (CIC) Drugs contains:
Analysis and forecast of Chronic Idiopathic Constipation (CIC) Drugs market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Chronic Idiopathic Constipation (CIC) Drugs market;
Assessment and forecast of Chronic Idiopathic Constipation (CIC) Drugs market development;
Financial and business profiles of the leading companies in the Chronic Idiopathic Constipation (CIC) Drugs industry.
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/57738
Scope
- Up to date working Chronic Idiopathic Constipation (CIC) Drugs data by major regions in the world, the forecast of planned capacity additions by 2026
- The annual breakdown of capital expenditure spending on proposed Chronic Idiopathic Constipation (CIC) Drugs for the period 2018 to 2026
- Planned Chronic Idiopathic Constipation (CIC) Drugs additions and capital expenditure spending by key countries and companies across the world
- Planned capital expenditure spending on new Chronic Idiopathic Constipation (CIC) Drugs projects by region, key countries, and companies
- Details of major planned Chronic Idiopathic Constipation (CIC) Drugs projects in the world up to 2026
 Our Blogs: http://www.technicaltop.com/2018/05/11/chronic-idiopathic-constipation-cic-drugs-market-size-share-growth-analysis-and-forecast-2016-2022/
http://www.mobilecomputingtoday.co.uk/6340/chronic-idiopathic-constipation-cic-drugs-market-expanding-cagr-6-43-2017-2025-credence-research/